| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
The combination therapy of interferon (IFN) and ribavirin (RBV) is used to treat HCV infection, however, how RBV enhances the anti-HCV effects remains unknown. We therefore investigated whether RBV modifies IFN's anti-HCV action. We used plasmid-based HCV replication system, which express HCV genotype 1a full genome in HepG2 and Huh7 hepatoma cell lines. Ribavirin regulates HCV replication through the up-regulation of ISGs induced by enhancing autocrine IFN-β. The modulation of ISGs by RBV would help to establish a means of eliminating HCV.
|
